▮ DFV TERMINAL
--:--:-- UTC SIGN IN
F1 Terminal / HOOK

HOOK — HOOKIPA Pharma Inc.

—
OTC · Health Care · Pharmaceuticals · CIK 1760542 ·
Last close
$1.09
Market Cap
$10.87M
52W High
$1.20
52W Low
$1.00
ADV30
10,155
Next earnings
—
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunetherapeutics targeting infectious diseases based on its proprietary arenavirus platform. The company's immuno-oncology pipeline includes HB-700, a novel next-generation multi-KRAS mutant-targeting investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers; Eseba-vec, an investigational immunotherapeutic agent in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers with enrollment completed in a Phase 1/2 clinical trial; and HB-300, which targets self-antigens for the treatment of prostate cancer. It is also developing HB-400 for the treatment of Hepatitis B that is in Phase I of clinical trial; and HB-500 for the treatment of Human Immunodeficiency Virus (HIV) that is in Phase I of clinical trial. The company has a collaboration and license agreement with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products for the treatment, cure, diagnosis, or prevention of the hepatitis B virus (HBV) and the HIV. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Jun 2025 6,795,000 — -6,512,000 -1,786,000 52,706,000 34,230,000 24,022,000
Mar 2025 2,004,000 — -17,514,000 -15,427,000 61,256,000 40,276,000 27,176,000
Dec 2024 1,354,000 — -16,692,000 -24,950,000 82,545,000 39,684,000 31,331,000
Sep 2024 4,703,000 — -15,411,000 -13,841,000 109,730,000 59,750,000 37,928,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-45,526,000
Investing CF
$-53,000
Financing CF
$-443,000
CapEx
$-53,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.73
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-429,978,000
Inventory
—
Receivables
$9,503,000
ST Investments
—
EBIT TTM
$-56,110,000
Pretax Income TTM
$-56,110,000
Interest Exp TTM
$0
Analysts
—

Yahoo Snapshot (yfinance, live)

Total Revenue
$9,351,000
EBITDA
$-72,401,000
Free Cash Flow
$-32,811,376
Enterprise Value
$-25,417,384
Total Cash
$40,276,000
Total Debt
$596,000
Shares Out
9,976,985
Trailing EPS
$-4.83
Book Value
$2.71
ROE
-105.8%
ROA
-45.2%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2024 43,946,000 -37,391,000 -43,503,000 82,545,000 31,331,000 — -76,978,000
Dec 2023 20,129,000 -73,735,000 -81,580,000 161,337,000 71,480,000 — -57,524,000
Dec 2022 14,249,000 -65,239,000 -64,915,000 170,454,000 67,937,000 — -19,997,000
Dec 2021 18,448,000 -71,950,000 -75,665,000 126,045,000 36,453,000 — -66,016,000

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-5.43

Peers — same industry

TickerNameMarket CapLastDaily %
BIVI BIOVIE INC. $10.86M $1.44 —
KAPA Kairos Pharma, LTD. $11.07M $0.52 —
APRE Aprea Therapeutics, Inc. $11.27M $0.91 —
PBM PSYENCE BIOMEDICAL LTD. $10.30M $4.49 —
BFRI Biofrontera Inc. $10.18M $0.80 —

News headlines (Yahoo Finance, 1h cache)

HOOKIPA Pharma Announces Completion of Sale of Oncology Assets to NeoTrail Therapeutics
2026-03-26 11:00 · Yahoo
HOOKIPA Pharma Announces Sale of Oncology Assets to NeoTrail Therapeutics
2026-02-03 13:30 · Yahoo
HOOKIPA Pharma Announces Completion of Sale of HBV and HIV Assets to Gilead
2025-10-31 12:00 · Yahoo
HOOKIPA Pharma Announces Intention to Voluntarily Delist and Deregister its Common Stock
2025-07-18 20:05 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.
SEC EDGAR filings → · StockAnalysis.com → · OpenInsider →